Library Of American University Of Madaba
Your cart is empty.
Humbert, Marc.
Pharmacotherapy of Pulmonary Hypertension [electronic resource] / edited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch. - IX, 576 p. 66 illus., 56 illus. in color. online resource. - Handbook of Experimental Pharmacology, 218 0171-2004 ; .
Preface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.
9783642386640
Medicine.
Medical laboratories.
Toxicology.
Pharmaceutical technology.
Internal medicine.
Pneumology.
Biomedicine.
Pharmacology/Toxicology.
Pharmaceutical Sciences/Technology.
Internal Medicine.
Pneumology/Respiratory System.
Laboratory Medicine.
Molecular Medicine.
RM1-950
615
Pharmacotherapy of Pulmonary Hypertension [electronic resource] / edited by Marc Humbert, Oleg V. Evgenov, Johannes-Peter Stasch. - IX, 576 p. 66 illus., 56 illus. in color. online resource. - Handbook of Experimental Pharmacology, 218 0171-2004 ; .
Preface.- Part I. Pulmonary hypertension: conceptual bases of the disease. Pulmonary hypertension: definition, classification, and epidemiology. Pulmonary hypertension: pathophysiology and signalling pathways. Pulmonary hypertension: pathology. Pulmonary hypertension: biomarkers. Pulmonary hypertension: animal models -- Part II. Pulmonary hypertension: established therapies. General supportive care. Calcium channel blockers. Prostacyclins. Endothelin receptor antagonists. Phosphodiesterase 5 inhibitors -- Part III. Pulmonary hypertension: novel pathways and emerging therapies Soluble guanylate cyclase stimulators. Therapeutics targeting dysregulated redox equilibrium and endothelial dysfunction (NOXs, sGC activators, GSNOR). Rho-kinase inhibitors. Serotonin transporters and serotonin receptors. PDGF inhibitors. Novel anti-proliferative strategies beyond imatinib. Immunosuppressive agents. Vasoactive peptides. Inhibitors of cGMP/cAMP metabolism (MRP4, MRP5, PDE1). Old targets re-visited. Stem cells and cell based therapy -- Part IV. Conclusions and Outlook. Pulmonary hypertension: evidence-based management in the modern era and future directions.
9783642386640
Medicine.
Medical laboratories.
Toxicology.
Pharmaceutical technology.
Internal medicine.
Pneumology.
Biomedicine.
Pharmacology/Toxicology.
Pharmaceutical Sciences/Technology.
Internal Medicine.
Pneumology/Respiratory System.
Laboratory Medicine.
Molecular Medicine.
RM1-950
615